News about 'mdr'

Researchers at the Center for Tuberculosis Research located at Johns Hopkins University School of Medicine have shown that heart medication, verapamil administered in combination with bedaquline lowers the toxicity of the TB drug without altering its efficacy. The paper, titled ‘ Verapamil...

Scientists at Janssen Pharmaceutica have characterized a novel resistance mechanism to Bedaquiline (BDQ), a second line antibiotic for the treatment of MDR-TB. The research study , published in Plos One , showed that tuberculosis resisted BDQ treatment by developing a mechanism to pump the drug out...

The European Commission has approved Delaminid (Deltyba™) for use in patients suffering from MDR-TB. Delamanid was developed by Otsuka Pharmaceutical Co., Ltd., a Japanese pharmaceutical company dedicated to drug discovery for tuberculosis. The press release from Otsuka can be found here Related...

TB Alliance has announced that it will conduct a landmark Phase 3 clinical trial aimed at shortening the treatment of drug sensitive and MDR-TB. The trial known as STAND (Shortening Treatments by Advancing Novel Drugs) will test the PaMZ drug regimen composed of two drug candidates not yet approved...

Vadim Makarov et. al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones . EMBO Molecular Medicine. 2014. March 1; 6(3). doi: 10.1002/emmm.201303575 A new antibiotic, labeled ‘PBTZ169’, has been shown to be effective against drug sensitive and MDR-tuberculosis...

The European Medicines Agency (EMA) has recently approved Sirturo (bedaquiline) for conditional use in the European Union for adults suffering from pulmonary MDR-TB. The press release from Multimedia News Release can be found at: http://www.multivu.com/mnr/65014-sirturo-treatment-multi-drug-...

Richard E. Lee et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux . Nature Medicine. 2014. March 6; 20(152). doi:10.1038/nm.3458 Abstract: Although the classical antibiotic spectinomycin is a potent bacterial protein synthesis inhibitor, poor...

Source: European Medicines Agency http://www.ema.europa.eu On 21 November 2013, the Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional marketing authorisation for the medicinal product Deltyba for the treatment of lung infections due to multidrug-...

Click to access report. This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and financing TB prevention, care and control at global, regional...

Source: Bloomberg http://www.bloomberg.com/news/2013-07-26/otsuka-s-drug-resistant-tb-treatment-fails-to-win-ema-nod.html Otsuka’s Drug-Resistant TB Treatment Fails to Win EMA Nod Otsuka Holdings Co. (4578) failed to win the backing of a European Medicines Agency panel for the Delamanid medicine...

Yesterday, the US National Public Radio posted online two insightful pieces on tuberculosis. What It Takes To Cure Drug-Resistant Tuberculosis Treating The ‘Body And Soul’ In A Russian TB Prison Please check it out and pass along.

Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB) . Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a...

Click here to access full report Source: Treatment Action Group The Tuberculosis Treatment Pipeline June 2013 Better than Ever Is Not Good Enough By Erica Lessem Introduction In December 2012, tuberculosis (TB) treatment reached a historic landmark with the first approval by a stringent regulatory...

From the Stop TB Parntership News: The World Health Organization (WHO) has issued interim guidance on the use of bedaquiline, a new tuberculosis drug, for the treatment of multidrug-resistant tuberculosis (MDR-TB). Bedaquiline was granted accelerated approval by the United States Food and Drug...

MSF Scientific Day 2013 will be streamed live online from the Royal Society of Medicine, London, UK, from 09.00am – 06.00pm (GMT+1) on 10 th May 2013 http://www.msf.org.uk/Scientific_Day.aspx MSF Scientific Day is a unique opportunity to showcase medical and scientific research carried out in MSF...